Recent Updates
Recently added Catalysts
ABBV

Document AbbVie Inc. Guidance Including the Impact of Acquired IPR D and Milestones Expense Incurred During the Second Quarter of 2022 (Unaudited) (In millions, except per share data) Quarter Ended

Key Takeaway: Guidance Including the Impact of Acquired IPR D and Milestones Expense Incurred During the Second Quarter of 2022 (Unaudited) (In millions, except per share data) Quarter Ended June 30, 2022 Full-Year Ended December 31, 2022 Acquired IPR D and Milestones Expense Adjusted Di

Full Press Release Details

Guidance Including the Impact of Acquired IPR D and Milestones Expense Incurred During the Second Quarter of 2022
(Unaudited) (In millions, except per share data)
Quarter Ended June 30, 2022 Full-Year Ended December 31, 2022
Acquired IPR D and Milestones Expense Adjusted Diluted EPS Range Acquired IPR D and Milestones Expense Adjusted Diluted EPS Range
Low High Low High
Previously announced guidance excluding Q2 2022 acquired IPR D and milestones expense $ - $ 3.38 $ 3.42 $ 145 $ 13.92 $ 14.12
Q2 2022 acquired IPR D and milestones expense 269 (0.14) (0.14) 269 (0.14) (0.14)
Guidance including Q2 2022 acquired IPR D and milestones expense a $ 269 $ 3.24 $ 3.28 $ 414 $ 13.78 $ 13.98
a The Company's 2022 adjusted diluted EPS guidance excludes any impact from acquired IPR D and milestones expense that may be incurred beyond the second quarter of 2022, as both cannot be reliably forecasted.
Last updated: Jun 30, 2022